Therapy Areas
Onxeo announces publication of shareholder newsletter
21 January 2020 -

Onxeo S.A (CPH:ONXEO) (Paris:ONXEO), a clinical-stage biotechnology company, announced on Monday the publication of its shareholder letter.

According to the company, in this new issue, readers will find out about Onxeo's perspectives for 2020 and the clinical development plan of AsiDNA, notably about an upcoming clinical study designed to evaluate the effect of AsiDNA in combination with niraparib on the abrogation of tumour resistance to this PARP inhibitor, approved as a second d line maintenance therapy for recurrent ovarian cancer.

Onxeo develops innovative oncology drugs targeting tumour DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR).

Login
Username:

Password: